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A B S T R A C T
The use of sensitive biomarkers to monitor skeletal muscle toxicity in preclinical toxicity studies is
important for the risk assessment in humans during the development of a novel compound. Skeletal
muscle toxicity in Sprague Dawley Rats was induced with cloﬁbrate at different dose levels for 7 days to
compare standard clinical pathology assays with novel skeletal muscle and cardiac muscle biomarkers,
gene expression and histopathological changes. The standard clinical pathology assays aspartate
aminotransferase (AST), alanine aminotransferase (ALT), and creatine kinase (CK) enzyme activity were
compared to novel biomarkers fatty acid binding protein 3 (Fabp3), myosin light chain 3 (Myl3), muscular
isoform of CK immunoreactivity (three isoforms CKBB, CKMM, CKMB), parvalbumin (Prv), skeletal troponin
I (sTnI), cardiac troponin T (cTnT), cardiac troponin I (cTnI), CKMM, and myoglobin (Myo). The biomarker
elevations were correlated to histopathological ﬁndings detected in several muscles and gene expression
changes. Cloﬁbrate predominantly induced skeletal muscle toxicity of type I ﬁbers of low magnitude.
Useful biomarkers for skeletal muscle toxicity were AST, Fabp3, Myl3, (CKMB) and sTnI. Measurements of
CK enzyme activity by a standard clinical assay were not useful for monitoring cloﬁbrate-induced skeletal
muscle toxicity in the rat at the doses used in this study.
ã 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A biological marker or biomarker is deﬁned as a characteristic
that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmaco-
logic responses to a therapeutic intervention (Biomarkers Deﬁ-
nitions Working Group, Atkinson et al., 2001). Correlation of
biomarker measurements to histopathological changes induced by
these toxicants is important to determine the speciﬁcity and
sensitivity of these biomarkers. The FDA expert working group
deﬁned several criteria, which should be complied for useful
biomarkers. An ideal biomarker has a high predictive andAbbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase;
BID, “bis in die” (latin) means twice daily; CK, and creatine kinase; CK, creatine
kinase; cTnI, cardiac troponin I; cTnT, cardiac troponin T; DD, dosing day; ELISA,
enzyme-linked immunosorbent assay; FABP3, fatty acid binding protein 3; HE,
hematoxylin and eosin; HMG-Co A, b-hydroxy-b-methylglutaryl coenzyme A; IHC,
immunohistochemistry; Myl3, myosin light chain 3; Myo, myoglobin; Prv,
parvalbumin; QD, “quaque die” means once daily; Rpm, Revolutions per minute;
RNA, ribonucleic acid; sTnI, skeletal troponin I; V., Vena.
* Corresponding author at: AbbVie Deutschland GmbH & Co. KG, Knollstraße,
67061 Ludwigshafen, Germany.
E-mail address: karen.bodie@abbvie.com (K. Bodié).
http://dx.doi.org/10.1016/j.etp.2016.03.001
0940-2993/ã 2016 The Authors. Published by Elsevier GmbH. This is an open access artic
4.0/).diagnostic value and a low rate of false-negative or false-positive
results. A useful biomarker should be speciﬁc, sensitive, predictive,
robust, bridging preclinical and clinical trials and non- or minimal-
invasive and accessible (Wallace et al., 2004).
The identiﬁcation of sensitive safety biomarkers in preclinical
toxicity studies to monitor toxicological effects in human subjects
during clinical studies becomes more and more indispensable. The
identiﬁcation and qualiﬁcation of sensitive biomarkers to monitor
skeletal muscle toxicity is an important factor for the clinical
development if skeletal muscle toxicity is detected pre-clinically.
ALT and AST are indicators of hepatocellular injury, but both,
especially AST are also present in skeletal and cardiac muscle. CK is
present in all types of muscle, in the brain and nerves. CK catalyzes
the conversion of creatine phosphate to creatine and adenosine
triphosphate (ATP) in order to provide an energy source for active
muscles (Jackson, 2007). Fatty acid binding protein 3 (Fabp 3)
modulates the fatty acid uptake in muscle cells (skeletal muscle
and heart) but also in other cells (liver, brain, small intestine). Pritt
et al. (2008) showed that Fabp3 in combination with other skeletal
muscle biomarkers was predictive for skeletal muscle necrosis.
Myosin, a protein of muscle tissue, formes contractile bundles with
actin ﬁlaments in the cytoplasm of myoﬁbers. Each myosin
molecule consists of six polypeptide chains: two identical heavyle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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the myosin light chain 3 of cardiac and type I skeletal muscle ﬁbers
(http://www.ncbi.nlm.nih.gov/gene/4634). Skeletal troponin is
one major accessory protein involved in Ca2+ regulation in
vertebrate skeletal muscle. It is a complex of three polypeptides,
troponin T, I and C (named for their Tropomyosin-binding,
Inhibitory and Calcium-binding activities). Troponin I binds to
actin (Alberts et al., 1989). The cardiac troponins have similar
composition to the skeletal troponins in general, but they are
nearly absolute myocardial tissue speciﬁc (Wallace et al., 2004).
Prv is a calcium binding protein involved in the contraction and
relaxation cycle of type II muscle ﬁbers and is mainly found in
skeletal muscles (Huber and Pette, 1996). Myo is an abundant
heme-containing oxygen carrier expressed predominantly in
cardiac and type I skeletal muscle ﬁbers (Sorichter et al., 1999).
Theory behind for utility of these enzymes and proteins as
biomarkers is of course that they leak out into the serum in case of
skeletal muscle ﬁber damage.
Skeletal muscles of rats can be divided into slow-twitch (type I
ﬁber) and fast-twitch (type II) ﬁber types, according to the
expression of their particular myosin heavy chain (MHC) isoform
(Schiafﬁno and Reggiani, 1994). In comparison to humans, the rat
has a relatively low proportion of type I ﬁbers in all muscles
described in the literature (Staron et al., 1999; Eng et al., 2008),
whereas human muscles contain type I and type II muscle ﬁbers to
a more similar distribution in most muscles. Deeper portions have
a higher percentage of type I ﬁbers whereas more superﬁcial
muscles or portions of muscles have a higher amount of type II
muscle ﬁbers (Dahmane et al., 2005).
The slow isoform (type I ﬁber) is MHCI and the three fast
isoforms (type II ﬁbers) are MHCIIa, MHCIId, and MHCIIb. In some
reports, MHCIId has also been referred to as MHCIIx (Schiafﬁno
et al., 1989; De Nardi et al., 1993). Most ﬁbers express one MHC
isoform only, but single ﬁbers may also contain two MHC isoforms
(hybrid ﬁbers) (Staron and Pette 1986; Staron et al., 1999). In this
investigation, we only focused on the differentiation of type I and
type II muscle ﬁbers without distinguishing between the type II
subtypes or hybrid ﬁbers. Reports indicated that ﬁbrates in general
induce skeletal muscle toxicity of type I skeletal myoﬁbers (De
Souza et al., 2006). Generally in the rat, this ﬁber type is
represented by the soleus muscle consisting predominantly of
type I skeletal muscle ﬁbers (more than 80%) (Novák et al., 2010),
but other muscles of the hindlimb have locations where type I
muscle ﬁbers are present (Eng et al., 2008).
Several drugs are on the market, which are known to cause
skeletal muscle toxicity, for example lipid lowering drugs (e.g.
ﬁbrates and statins). Cloﬁbrate which is an agonists of the
peroxisome proliferator-activated receptors alpha (PPAR-a) is
used for the treatment of hyperglyceridemia and also causes a
favourable increase of high density cholesterol (Chapman, 2003).
Although generally well tolerated, the most important complica-
tions with cloﬁbrate are myopathies, ranging from myalgia, muscle
weakness, muscle tenderness and muscle cramps to destruction of
skeletal muscle (Rush et al., 1986). Standard clinical chemistry
analysis often shows signiﬁcant increases in CK and AST (SGOT)
activities in humans (Rush et al.,1986; Le Quintrec and Le Quintrec,
1991). The pathomechanism of cloﬁbrate-induced myopathy is still
poorly understood. Teräväinen et al. (1977) and Okada et al. (2007)
reported about morphologic and ultrastructural changes of
cloﬁbrate-induced myopathy in rats. The ﬁber type selectivity of
fenoﬁbrate to affect type I muscle ﬁbers was shown to be
consistent with increased fatty acid uptake and beta-oxidation,
which represent the major clinical beneﬁts of hypolipemic
compounds (De Souza et al., 2006).Because of the relatively low representation of type I ﬁbers in
the rat, cloﬁbrate was chosen for induction of skeletal muscle
toxicity of low magnitude.
The goal of this investigation was to evaluate a set of skeletal
muscle biomarkers (mentioned above) in rats with induced
skeletal muscle toxicity of low magnitude on protein and gene
expression level with morphologic and immunohistochemical
changes as well as the ﬁber type predeliction of cloﬁbrate-induced
myopathy in the rat.
2. Materials and methods
2.1. Animal husbandry
Twenty (experiment 1) and ten (experiment 2) male Sprague
Dawley (Crl:CD(SD)) rats approximately eight weeks old were
obtained from Charles River Laboratories (Sulzfeld, Germany).
Following physical examination by a veterinarian, the rats were
allowed to acclimate for seven days before the ﬁrst dosing.
All rats were individually housed in U-TempTM Type III cages
(Tecniplast S.p.A. Buguggiate, Italy), under barrier conditions with
bedding (dust-free softwood shavings; Ssniff Spezialdiäten GmbH,
Soest, Germany) containing chewing wood (Ssniff Spezialdiäten
GmbH) as enrichment under controlled conditions (temperature
22  2 C, humidity 55 10%, LD (light-dark) 12:12). The rats had ad
libitum access to a standard rodent diet (R/M-H, pellets1 Rodent
Diet, Ssniff Spezialdiäten GmbH) and to autoclaved tap water. Food
was removed overnight for 18 h prior to blood withdrawal (2–3 h
prior to the dark phase). The rats were moved to clean cages once
per week. All rats were observed at least once daily for general
condition. Body weights were measured upon arrival and on the
day of terminal blood withdrawal.
Rats were housed, treated, and sacriﬁced complying with the
regulations of Germany and the European Union, including the
German Animal Welfare Act that implements the European
Council Directive 86/609/EEC. AbbVies’s laboratory animal pro-
grams in general as well as the local facility where the experiments
of this study were conducted were accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care
International (AAALAC) during the conduct of the study and all
experiments were conducted according to the standards put forth
in the National Research Council’s Guide for the Care and Use of
Laboratory Animals and were approved by the government of
Rhineland-Palatinate.
2.2. Test material
Cloﬁbrate (purity 98.8%) was obtained from TCI Europe N.V.
(Zwijndrecht, Belgium) and was formulated for dosing as suspen-
sion in miglyol-812. The formulations were prepared weekly and
stored at room temperature (RT) protected from light.
2.3. Treatment
In experiment 1, the rats were randomly allocated to four
groups with ﬁve animals each group and were treated over a period
of at least seven days via gavage. The control group received the
vehicle (miglyol-812) and three dose groups received cloﬁbrate at
doses of 150 mg/kg QD, 150 mg/kg BID, and 500 mg/kg QD. In
experiment 2, rats were randomly allocated to two groups with ﬁve
animals each group. The control group received the vehicle
(miglyol-812) and the dose group received cloﬁbrate at a dose of
500 mg/kg QD over a period of at least seven days via gavage. The
animals were fasted over night before scheduled necropsies.
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From all rats, samples of blood (approximately 0.8 ml/rat) were
collected from the V. sublingualis on Baseline and Dosing Day 7
(DD 7) for clinical chemistry and biomarker analysis.
2.5. Urine collection
In experiment 2, urine was collected once in the baseline
period, on DD 7 before necropsy. Each surviving rat was
maintained in a metabolism cage without food but with access
for water over night. The urine samples were stored at 2–8 C and
subsequently deeply frozen.
2.6. Clinical pathology and biomarker
Analysis was performed on the same day of blood collection. In
experiment 1, hematology parameters were evaluated with a
Siemens ADVIA 120 Analyzer (Siemens Healthcare Diagnostics
GmbH, Eschborn, Germany) with Multispecies software. Complete
blood (cell) counts (CBC) were performed. Coagulation proﬁles
were evaluated with a Thrombolyser (Trinity Biotech GmbH,
Lemgo, Germany). Serum biochemical proﬁles were evaluated
with a Hitachi 917 (Roche Diagnostics GmbH, Mannheim,
Deutschland) or with a cobas c501 (Roche Diagnostics GmbH,
Mannheim, Deutschland—experiment 2). In both experiments, for
biomarker analysis one hundred mL serum was stored at 80 C.
Biomarker analysis was performed using Meso Scale Discovery1
Multi Spot1 Assay system, Muscle Injury Panel 1 (rat; 2009) Assay
Kit for cTnI, cTnT, sTnI (skeletal muscle ﬁbers type I and type II).Table 1
Experiment 1: Selected clinical chemistry parameter and biomarker after 7-Day Treatm
Cloﬁbrate mg/kg
for 7 Days
Animalnumber ALT
U/L
AST
U/L
CK
U/L
Fabp3
ng/mL
Baseline Ranges 49–68 74–98 183–449 1.00–9
0 1001 49 84 427 1.53 
0 1003 45 83 344 1.74 
0 1005 41 86 353 3.14 
0 1007 60 79 299 4.99 
0 1009 52 79 303 2.45 
Mean 49 (59) 82 (94) 345 (428) 2.77 (4
%Ctrl – – – – 
150 QD 2001 51 78 245 12.32 
150 QD 2003 55 69 220 6.40 
150 QD 2005 42 79 260 7.78 
150 QD 2007 60 77 291 7.44 
150 QD 2009 43 84 247 3.25 
Mean 50 (55) 76 (87) 253*H (307) 7.44 (3
%Ctrl 2 6 27 196 
150 BID 3001 58 129 151 15.95 
150 BID 3003 47 87 266 12.91 
150 BID 3005 62 118 134 19 
150 BID 3007 41 76 225 5.29 
150 BID 3009 54 83 237 1.15 
Mean 53 (53) 99 (82) 203#H (264) 10.86 (
%Ctrl 6 20 41 292 
500 QD 4001 67 175 211 10.28 
500 QD 4003 76 178 269 18.68 
500 QD 4005 107 269 221 23.65 
500 QD 4007 70 183 230 16.99 
500 QD 4009 61 104 172 4.75 
Mean 76+H (57) 182#H (93) 221+H (387) 14.87+
%Ctrl 54 121 36 437 
Baseline means of treated animals were stated in parenthesis. *H = Dunnett Exact H
Signiﬁcance: 0.001 level. +H = Dunnett Exact Homogenous Test Signiﬁcance: 0.01 levelFABP3, Myl3 and Muscle Injury Panel 2 (rat; 2009) Custom Assay
Kit for parvalbumin and CK (three isoforms CKBB, CKMM, CKMB)
(MesoScale Diagnostics LLC., Gaithersburgh, MD, USA) (experi-
ment 1) according to the manufacturer protocol using a Sector
Imager 6000 reader. In experiment 2, Muscle injury panel 1 (MSD
MesoScale Discovery, 2011) for FABP3, Myl3, and sTnI (skeletal
muscle ﬁbers type I and type II) and an ELISA for determination of
CKMM (RAT CK-MM ELISA KIT, Life Diagnostics, Inc., West Chester,
PA, USA) and myoglobin (RAT MYOGLOBIN ELISA, Life Diagnostics,
Inc., West Chester, PA, USA) were performed according to the
manufacturer protocol using a Sector Imager 6000 reader.
2.7. Urinary biomarker
In experiment 2, urinary myoglobin (RAT MYOGLOBIN ELISA,
Life Diagnostics, Inc., West Chester, PA, USA) was evaluated
according to the manufacturer protocol using a Sector Imager
6000 reader.
2.8. Statistical evaluation
Statistical analysis was performed using the PRISTIMA system
(Xibion ToxPath System PRISTIMA1 System, Morris Plains, NJ,
USA). Summary statistics and results of the statistical analyses
were presented in data tables. Data collected at each time point
was analyzed separately. Statistical tests were used as described
below to compare control group data with those of the test item-
treated groups. Dunnett’s test was used to analyze clinical
chemistry parameter and biomarkers (Dunnett, 1955, 1964;
Dunlap et al., 1981).ent (serum).
Myl3
ng/mL
Prv
ng/mL
CK (three isoforms)
ng/mL
sTnI (1/2)
ng/mL
.99 0.16–0.82 8.69–40.67 2.07–37.99 0.00–1.81
0.29 11.38 6.71 0.29
0.22 32.23 2.64 0.12
0.39 16.72 18.23 0.69
0.30 19.01 14.70 0.31
0.62 33.25 10.35 0.57
.29) 0.36 (0.26) 22.52 (17.71) 10.53 (14.23) 0.40 (0.69)
– – – –
0.85 15.53 70.34 0.71
0.27 11.64 50.68 0.40
0.21 10.33 29.88 0.43
0.56 14.55 42.78 0.35
0.24 17.68 23.31 0.18
.12) 0.43 (0.37) 13.95 (19.58) 43.40 (5.98) 0.41 (0.10)
17 38 312 5
13.19 13.27 34.91 0.77
1.36 8.48 83.96 0.51
17.56 13.39 58.03 0.88
0.58 11.14 22.32 0.47
0.55 7.31 2.14 0.21
3.01) 6.65 (0.49) 10.72 (13.70) 40.27 (6.93) 0.57 (0.14)
1726 52 283 43
5.10 92.32 53.33 5.86
13.13 39.03 40.26 4.83
28.69 90.22 48.99 6.27
11.19 153.92 114.89 11.42
1.60 20.64 19.09 2.12
H (2.86) 11.94*H (0.35) 79.23*H (14.63) 55.31*H (15.50) 6.10#H (0.43)
3181 252 425 1440
omogenous Test Signiﬁcance: 0.05 level. #H = Dunnett Exact Homogenous Test
. Animals in bold had degeneration/necrosis myoﬁber (at least in m. soleus).
Table 2
Experiment 1: Selected histopathology of affected skeletal muscles after 7-Day Treatment.
Cloﬁbrate mg/kg
for 7 Days
Animalnumber Histopathology Finding M. gastrocnemius M. soleus M. quadriceps M. triceps Mm. intercostales Diaphragm
Myoﬁber Severity Score and Distribution
150 BID 3001 Degeneration/necrosis 1m 1m 1m NAD NAD 1f
150 BID Regeneration NAD 1m 1m 1m NAD NAD
Vacuolation NAD 1f NAD NAD NAD NAD
150 BID 3003 Regeneration NAD 1m NAD NAD NAD NAD
150 BID 3005 Regeneration NAD 1m NAD NAD NAD 1m
Vacuolation NAD 1f NAD NAD NAD NAD
500 QD 4001 Degeneration/necrosis NAD NAD 1m NAD NAD 1f
Regeneration NAD NAD 1m 1m NAD 1m
Vacuolation NAD NAD 1m 1m NAD NAD
500 QD 4003 Degeneration/necrosis NAD 2m NAD NAD NAD NAD
Regeneration NAD 1m 1m 1m NAD 1m
Vacuolation NAD NAD 1m NAD NAD NAD
500 QD 4005 Degeneration/necrosis 1m 1m 2m 1m 1m 1f
Regeneration 1m 1m 2m 1m NAD 1m
Vacuolation NAD NAD 1m NAD NAD NAD
500 QD 4007 Degeneration/necrosis 1m NAD 1m 1m NAD NAD
Regeneration NAD 1m 2m 2m NAD 1m
Vacuolation NAD NAD 1m 1m NAD NAD
500 QD 4009 Degeneration/necrosis NAD 1m NAD NAD NAD 1f
Regeneration NAD 2m NAD NAD NAD 1m
Vacuolation NAD 1m NAD NAD NAD NAD
Histopathology scoring: NAD = nothing abnormal detected; 1 = minimal; 2 = mild; f = focal; m = multifocal.
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In experiment 1, on DD 8/9, respectively, and in experiment 2,
on DD 8, all rats were euthanised by exsanguination under deep
Isoﬂurane1 (Abbott GmbH & Co. KG, Wiesbaden, Germany)
anaesthesia. Eight% narcoren (Narcoren 16%, Merial GmbH,
Hallbergmoss, Germany diluted with 0.9% Sodiumchloride, B.
Braun Vet Care GmbH, Tuttlingen, Germany) was also used to
improve anesthesia. In experiment 1, soleus, gastrocnemius,
quadriceps, and triceps muscles of both hind- and forelimbs,
three portions of intercostal muscles, diaphragm, and heart were
removed. Muscles of the left hind- and forelimb, as well as left
intercostal, left portion of diaphragm, and one half of the heart
were ﬁxed in 10% neutral phosphate buffered formalin for light
microscopy and immunohistochemistry. The muscles wereTable 3
Experiment 2: Selected clinical chemistry parameter and biomarker after 7-Day Treatm
Cloﬁbrate mg/kg
for 7 Days
Animalnumber ALT
U/L
AST
U/L
CK
U/L
Baseline Ranges 35–45 72–191 201–
0 1001 35 83 162 
0 1003 30 67 160 
0 1005 33 76 187 
0 1007 27 68 115 
0 1009 28 67 130 
Mean 31 (41) 72 (112) 151 
%Ctrl – – – 
500 QD 3001 48 144 140 
500 QD 3003 50 139 155 
500 QD 3005 44 97 183 
500 QD 3007 47 101 116 
500 QD 3009 43 104 125 
Mean 46#H (41) 117 + H(130) 144 
%Ctrl 52 62 5 
Baseline means of treated animals were stated in parenthesis. *H = Dunnett Exact H
Signiﬁcance: 0.001 level. +H = Dunnett Exact Homogenous Test Signiﬁcance: 0.01 levelprepared and trimmed at necropsy, and one longitudinal and
one transversal section of each collected limb muscle (unilateral)
were evaluated. Muscles of the right hind- and forelimb, as well as
right intercostal, right portion of diaphragm, and one half of the
heart were ﬂash frozen in liquid nitrogen for gene expression
proﬁling.
In experiment 2, soleus, gastrocnemius, quadriceps, and triceps
muscles of both hind- and forelimbs, as well as three portions of
longissimus dorsi muscles (left and right), diaphragm, and heart
were removed and ﬁxed in 10% neutral phosphate buffered
formalin for light microscopy and immunohistochemistry.
To assess the muscles according to their anatomic composition
in the limb and having the appropriate area of interest on the slide,
the muscles were trimmed after ﬁxation of the whole limbs and
oriented according to their anatomic composition.ent (serum).
Fabp3
ng/mL
Myl3
ng/mL
sTnI (1/2)
ng/mL
Myo
ng/mL
1626 0.65–3.88 0.14–0.74 0.19–0.76 0.00–9.15
1.15 0.13 0.19 0.00
1.35 0.40 0.19 0.00
1.04 0.18 0.19 0.00
0.97 0.09 0.19 0.00
1.19 0.34 0.19 0.00
(681) 1.14 (2.07) 0.23 (0.32) 0.19 (0.19) 0.00 (2.21)
– – – –
19.85 9.14 2.94 7.08
18.43 4.71 4.06 13.75
6.57 2.33 1.27 11.67
4.73 2.51 1.11 1.74
7.93 2.47 3.08 2.24
(790) 11.50*H (1.24) 4.23*H (0.42) 2.49 (0.38) 7.30 (3.40)
909 1756 1212 –
omogenous Test Signiﬁcance: 0.05 level. #H = Dunnett Exact Homogenous Test
.
K. Bodié et al. / Experimental and Toxicologic Pathology 68 (2016) 289–299 2932.10. Light microscopy
Formalin ﬁxed tissues were embedded in paraplast (parafﬁn)
and sectioned at 3–4 mm thickness using a rotation microtome
(MICROM International GmbH, Walldorf, Germany). Serial sections
were stained with hematoxylin and eosin (HE) (Richard Allan
Scientiﬁc Hematoxylin 7211, Kalamazoo, MI, USA; Eosin-Y alcohol-
ic, Kalamazoo, MI, USA), or were stained for ﬁber typing using the
following immunohistochemical technique. After antigen retrival
of the de-parafﬁnized sections (two minutes full pressure in a
pressure cooker containing citrate buffer at pH 6.0 (Citric acid-
Monohydrate, Merck KGaA, Darmstadt, Germany)), endogenous
peroxidase activity was blocked by incubation with normal goat
serum (DAKO, Glostrup, Denmark) at 1:20 for 20 min. Mouse
monoclonal anti-myosin to fast skeletal muscle antibody (SIGMA,
Saint Louis, MI, USA) or Mouse monoclonal anti-myosin to slow
skeletal muscle antibody (SIGMA) at a dilution of 1:300 or 1:4000,
or Mouse monoclonal Fatty Acid Binding Protein 3 (human Fabp3,
Hycult Biotech, Beutelsbach, Germany) 1:25 were applied for one
hour. This was visualized by applying Biotin SP-Goat anti Mouse
(Dianova GmbH, Hamburg, Germany) at 1:800 for 30 min, followed
by alkaline phosphatase streptavidin (Vector Laboratories Inc.,
Burlingame, CA, USA) for 30 min, followed by fast red substrate
(Biogenex, San Ramon, CA, USA) for 15 min, followed by counter-
staining with Mayers hematoxylin (Merck KGaA, Darmstadt,
Germany) for 1 min. The incubation steps were performed at
room temperature, and between each step sections were rinsed
carefully in TRIS washing buffer (Trishydroxymethyl-aminome-
than, Merck KGaA, Darmstadt, Germany) at pH 7.6. HE sections
were mounted with Pertex (Medite GmbH, Burgdorf, Germany),Table 4
Experiment 2: Selected histopathology of affected skeletal muscles after 7-Day Treatm
Cloﬁbrate
mg/kg
for 7 Days
Animalnumber Histopathology
Finding
M. gastrocnemius
intermedius (bilateral)
M. soleu
(bilateral
Myoﬁber Severity Score and Distribution
500 QD 3001 Degeneration/
necrosis
2m 2m 
Regeneration 2m 2m 
Vacuolation 1m 1m 
Variation 2m 2m 
500 QD 3003 Degeneration/
necrosis
2m* 2m 
Regeneration 1m 2m 
Vacuolation NAD 2m 
Variation,
diameter
1m* 2m 
500 QD 3005 Degeneration/
necrosis
NAD 1m 
Regeneration 1m* 1m 
Vacuolation NAD 1m*
Variation,
diameter
NAD 1m 
500 QD 3007 Degeneration/
necrosis
NAD 1m 
Regeneration 1m 1m 
Vacuolation NAD 2m 
Variation,
diameter
1m 1m 
500 QD 3009 Degeneration/
necrosis
1m 1m 
Regeneration 1m 1m 
Vacuolation NAD 1m*
Variation,
diameter
1m 1m 
Histopathology scoring: NAD = nothing abnormal detected; 1 = minimal; 2 = mild; f = focimmunohistochemical sections were mounted with Kaiser’s
glycerol gelatine (Merck KGaA, Darmstadt, Germany). Histopa-
thology evaluation was performedusing an Olympus
BX50 Microscope (Olympus Optical Co., GmbH, Hamburg,
Germany) and selected slides were scanned using a ScanScope1
XT (Aperio Technologies Inc., CA, USA).
2.11. Skeletal muscle and heart histopathological analysis
A grading system using ﬁve severity grades (minimal, mild,
moderate, marked, severe) and nothing abnormal detected (NAD)
was applied to the histopathological analysis.
2.12. Gene expression proﬁling
Experiment 1: Isolation of total RNA from frozen M. soleus
samples was performed using the standard protocol from Qiagen
Inc. (Valencia, CA, USA). RNA preparation and analysis was done
according to the Affymetrix Inc. protocol (Santa Clara, CA, USA).
The integrity of the RNA from the samples was determined using a
Agilent 2100 Bioanalyser (Agilent Technologies, Foster City, CA,
USA). cDNA was prepared from 5 mg of total RNA using the
Superscript system from Invitrogen Life Technologies (Carlsbad,
CA, USA). Following this, labelled cRNA was synthesized from the
cDNA using the Enzo RNA Transcript Labeling Kit (Enzo Life
Sciences, Farmingdale, NY, USA) according to the manufacturer‘s
instructions. Approximately 20 mg of cRNA was then fragmented at
94 C for 35 min. Labelled cRNA was hybridized overnight at 45 C
using Affymetrix Rat Genome 2.0 microarrays with approximately
31,000 probe sets (Waring et al., 2006).ent.
s
)
M. quadriceps, vastus
intermedius
(bilateral)
M. triceps,
medial portion
(bilateral)
M. longissimus dorsi,
medial portion
(bilateral)
Diaphragm
1m NAD 1m 1m
1m 1m* 2m 2m
1m* NAD 1m 1m
2m NAD 2m 2m
2m NAD 1m 1m
1m NAD 1m 1m
1m NAD 1m NAD
1m NAD NAD 2m
1m* 1m* 1m 1m
1m* NAD 1m 1m
1m NAD 1m NAD
1m* NAD 2m NAD
1m NAD 1m NAD
1m NAD 1m 1m
1m NAD 1m NAD
1m NAD 2m NAD
1m NAD NAD NAD
1m NAD 1m* 1m
1m* NAD NAD NAD
1m NAD NAD 2m
al; m = multifocal. * = unilateral.
Table 5
Experiment 2: Urinary myoglobin after 7-Day Treatment.
Cloﬁbrate mg/kg
for 7 Days
Animalnumber Myo
ng/mL
Baseline Ranges 0–2.21
0 1001 0.86
0 1003 0.09
0 1005 1.84
0 1007 0.90
0 1009 0.69
Mean 0.88
%Ctrl –
500 QD 3001 4.32
500 QD 3003 5.00
500 QD 3005 2.56
500 QD 3007 3.63
500 QD 3009 2.78
Mean 3.66#H
%Ctrl 318
Baseline means of treated animals were stated in parenthesis. #H = Dunnett Exact
Homogenous Test Signiﬁcance: 0.001 level.
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3.1. Clinical observations
In experiment 1, all animals receiving 500 mg/kg cloﬁbrate QD
showed mild to severe gait disorders from DD 2 to DD 7. In
experiment 2, all animals receiving 500 mg/kg cloﬁbrate QD
showed mild to moderate gait disorders on DD 1 and DD 5 to DD 7.Fig. 1. Key features of cloﬁbrate-induced myoﬁber alterations on cellular level (HE stain
inﬂammatory cell inﬁltration, loss of cross striation (arrow) (200x). B: Treated animal (150
nuclei (arrow) (200x).3.2. Clinical pathology and biomarker in serum (and histopathological
correlation)
Experiment 1: CBC and Coagulation proﬁling revealed no
signiﬁcant changes from the physiological range (Abbvie Deutsch-
land GmbH & Co. KG reference range) for rats of this age and strain.
In clinical chemistry, one animal at 500 mg/kg cloﬁbrate QD had a
two-fold increase in ALT on DD 7. There was a mild increase in AST
serum levels in two animals at 150 mg/kg cloﬁbrate BID and a two
to 3.5-fold increase in all animals at 500 mg/kg cloﬁbrate QD. The
mild increases in AST correlated with histopathological ﬁndings of
skeletal myoﬁber degeneration and necrosis at 150 mg/kg cloﬁ-
brate BID, except in animal 3005. Results of CK enzyme activity had
varying values in all dose groups including vehicle control at
Baseline and on DD. In animals of all groups treated with cloﬁbrate,
cholesterol and triglycerides were mildly decreased on Dosing Day
7 (data not shown), which was considered to be related to the
pharmacological properties of the compound.
Selected clinical chemistry parameter of experiment 1 are
shown in Table 1.
FABP3 was increased in three animals at 150 mg/kg cloﬁbrate
QD, in four animals at 150 mg/kg cloﬁbrate BID and in four animals
at 500 mg/kg cloﬁbrate QD compared to Baseline levels ranged
from approximately 3.1- to 11.2-fold. In general the
FABP3 increases correlated with histopathological ﬁndings of
degeneration and/or regeneration of skeletal myoﬁbers, except in
animal 2001 at 150 mg/kg cloﬁbrate QD with a minimal increase in
FABP3. The increases in FABP3 were minor with minimal skeletal
myoﬁber regeneration, but the group mean reached statistical
signiﬁcance with mild skeletal myoﬁber degeneration in animals
at 500 mg/kg cloﬁbrate QD compared to control mean (Table 1).
Myl3 had low values (<1.00 ng/mL) in Baseline and non-
affected animals. One animal (3005) at 150 mg/kg cloﬁbrate BID), M. soleus. A: Treated animal (500 mg/kg QD), longitudinal section, necrosis and
 mg/kg BID), longitudinal section, degeneration and regeneration, centralized row of
Fig. 2. Overview of M. gastrocnemius and M. soleus (A, B) and M. quadriceps (C, D) as cross section (IHC ﬁber typing) showing the distribution of type I and type II myoﬁbers.
A: IHC with skeletal myosin slow, type I myoﬁbers in fast red (10x). B: IHC with skeletal myosin fast, type II myoﬁbers in fast red (10x). C: IHC with skeletal myosin slow, type I
myoﬁbers in fast red (10x). D: IHC with skeletal myosin fast, type II myoﬁbers in fast red (10x). 1: M. soleus, 2: M. gastrocnemius, 3: M. gastrocnemius intermedius, M.
Quadriceps including 4: M. Vastus intermedius, 5: M. Vastus medialis, 6: M. Vastus lateralis, 7: M. Rectus femoris.
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levels) without histopathological correlate, all other increases in
Myl3 correlated to skeletal myoﬁber degeneration, also if the
ﬁndings were minimal. The group mean reached statistically
signiﬁcance at 500 mg/kg cloﬁbrate QD compared to control mean(Table 1). In comparison to baseline levels the increases ranged
from approximately 4.5- to 136-fold in individual animals.
Prv had variable values between 8 and 40 ng/mL in Baseline
levels. Minimal skeletal myoﬁber degeneration and/or regenera-
tion correlated only in animal 4001 at 500 mg/kg cloﬁbrate QD to a
Fig. 3. Fibertype selectivity of cloﬁbrate-induced lesions in the M. soleus as cross section (IHC ﬁber typing). A: IHC with skeletal myosin slow (type I myoﬁbers in fast red),
degeneration/regeneration and vacuolation in skeletal myosin slow positive myoﬁbers (200x). B: IHC with skeletal myosin fast (type II myoﬁbers in fast red), degeneration/
regeneration and vacuolation in skeletal myosin fast negative myoﬁbers (200x).
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myoﬁber degeneration and/or regeneration at 500 mg/kg cloﬁ-
brate QD there were mild increases in prv with statistically
signiﬁcant difference in group mean compared to controls.In
comparison to baseline levels the increases ranged from approxi-
mately 5.9- to 9.6-fold in individual animals (Table 1).
CK immunoreactivity (three isoforms) had variable values up to
38 ng/mL in Baseline levels. There were remarkable increases in
two animals at 150 mg/kg cloﬁbrate QD and BID each, and in four
animals at 500 mg/kg cloﬁbrate QD (led to statistically signiﬁcance
at 500 mg/kg cloﬁbrate QD), compared to control and/or baseline
levels. In comparison to baseline levels the increases ranged from
approximately 2.1- to 11.3-fold in individual animals (Table 1).
There was no clear correlation of the CK immunoreactivity values
to the magnitude of the histopathological correlate, therefore
interpretation of CK immunoreactivity was considered question-
able.
Skeletal muscle troponin (sTNI) had low values (<1.81 ng/mL)
in Baseline and non-affected animals. Only animals with increases
of sTnI over 1.00 ng/mL had skeletal myoﬁber degeneration.
Animal 3001 at 150 mg/kg cloﬁbrate BID with minimal skeletal
myoﬁber degeneration and regeneration had no increase in sTnI
(false negative). In comparison to baseline levels, the increases
ranged from approximately 3.8- to 43-fold in individual animals.
The increases in sTNI group means were statistically signiﬁcant in
animals at 500 mg/kg cloﬁbrate QD compared to control means
(Table 1).
All cardiac troponins had values of zero or nearby zero in all
animals, which was consistent with no observed lesions exceeding
minimal background lesions in the heart.
Experiment 2:
For clinical chemistry, AST values were variable and animals at
500 mg/kg cloﬁbrate QD had elevated values in the baseline,
therefore the elevations were not considered related to cloﬁbrateadministration. Results of CK enzyme activity had varying values in
all dose groups including vehicle control at Baseline and on DD 7. In
animals of the group treated with cloﬁbrate, cholesterol was mildly
decreased on DD 7, which was considered to be related to the
pharmacological properties of the compound (data not shown).
Selected clinical chemistry parameter of experiment 2 are
shown in Table 3.
FABP3 was mildly increased in all animals at 500 mg/kg
cloﬁbrate QD compared to control levels and reached statistically
signiﬁcance when compared to control group mean. In comparison
to baseline levels, the increases ranged from approximately 3.8- to
30-fold in individual animals. The increased FABP3 values
correlated with the magnitude of histopathological ﬁndings in
skeletal myoﬁber of degeneration/necrosis and/or regeneration in
all animals. (Tables 3 and 4).
Myl3 was mildly statistically signiﬁcantly increased in animals
at 500 mg/kg cloﬁbrate QD (approximately 3.4- to 41-fold in
individual animals) compared to respective Baseline levels
(<0.74 ng/mL) and control animals, which correlated to severity
scores of histopathological ﬁndings of skeletal myoﬁber degener-
ation/necrosis and/or regeneration in all animals. (Tables 3 and 4).
sTNI was mildly increased was mildly statistically signiﬁcantly
increased in animals at 500 mg/kg cloﬁbrate QD (approximately
4.1- to 10-fold in individual animals) compared to respective
Baseline levels (<0.76 ng/mL) and control animals, which corre-
lated to severity scores of histopathological ﬁndings of skeletal
myoﬁber degeneration/necrosis and/or regeneration in all animals,
except animal 3009 at 500 mg/kg cloﬁbrate QD which had the
second highest sTNI value but only minimal histopathological
changes. The increases in sTNI were biologically signiﬁcant in
animals at 500 mg/kg cloﬁbrate QD compared to control levels
(Dunnett’s test of signiﬁcance is deﬁned for values with normal
variation. Since all control values for sTNI were 0.19 ng/mL per
deﬁnition of Dunnett’s test no calculation was performed)
Fig. 4. IHC with Fabp3 of cloﬁbrate-induced lesions in the M. soleus as longitudinal
section. Loss of cross striation and Fabp3 negative staining of degenerated skeletal
muscle ﬁbers (arrow) (200x).
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in the control group. In two animals at 500 mg/kg cloﬁbrate QD
Myo was higher than 9.15 ng/mL (Table 3). The increases ranges
from approximately 1.9- to 5.5 fold compared to individual
baseline values. The myoglobin increases correlated partially withTable 6
Experiment 1: Major Biochemical Pathways Perturbed in Muscle Upon Treatment with
Set Name P-value 
AMP Kinase: A Metabolic Master Switch 9.95E-08 
ChREBP & Regulation of Carbohydrate Metabolism 2.92E-07 
LXR & Adipocyte Differentiation 6.05E-07 
Regulation of Glucose Utilization 5.06E-06 
Xenobiotic Metabolism 2.76E-05 
Regulation of Fatty Acid Biosynthesis 1.16E-04 
Fatty Acid Biosynthesis & its Regulation 6.04E-04 
Glycolysis 9.26E-04 
Lipolysis: Mobilization of Triacylglycerols 1.29E-03 
Glucocorticoids & Glucose Metabolism 1.46E-03 
Bile Acid & Cholesterol Metabolism 1.50E-03 
Vascular Tissue Angiotensin System 1.60E-03 
Regulation of Aldosterone Biosynthesis 1.95E-03 
Insulin & Lipid Homeostasis 5.98E-03 
Bcr-Abl Signaling (Glevec Action) 6.26E-03 
Gluconeogenesis 7.56E-03 
SREBP, Regulation of Fatty Acids & Cholesterol Biosynthesis 7.56E-03 
Transportation of Lipids 1.27E-02 
Estrogen Receptor Signaling 1.35E-02 
LPS & IL-1 Induced Changes in Lipid Metabolism 1.55E-02 
Wnt/b-Catenin Signaling in Cancer Development 1.62E-02 
p53 Signaling 1.63E-02 
Adiponectin & Energy Metabolism 1.63E-02 histopathological ﬁndings of skeletal myoﬁber degeneration/
necrosis and/or regeneration. The higher myoglobin values did
not correlate with the higher severity scores in different skeletal
muscles (Tables 3 and 4).
All results for CKMM were under the lowest level of detection.
All cardiac troponins had values of zero or nearby zero in all
animals, which was consistent with no observed lesions exceeding
minimal background lesions in the heart.
3.3. Biomarker (and histopathological correlation) in urine
Experiment 2: Myo was statistically signiﬁcantly increased in
animals at 500 mg/kg cloﬁbrate QD compared to Baseline levels
(0–2.21 ng/mL) and control animals, which correlated to severity
scores of histopathological ﬁndings of skeletal myoﬁber degener-
ation/necrosis and/or regeneration in all animals. (Table 5).
3.4. Skeletal muscle and heart histopathological analysis/
immunhistochemistry
Experiment 1:
The number of muscles involved and the magnitude of skeletal
muscle ﬁber degeneration and/or regeneration and/or vacuolation
was higher in animals at 500 mg/kg cloﬁbrate QD compared to
animals at 150 mg/kg cloﬁbrate BID (Fig. 1; Table 2).
The muscles soleus, gastrocnemius, quadriceps, triceps and
diaphragm were affected to a different extent, whereas the
intercostal muscles were affected in only one animal. The ﬁndings
of myoﬁber degeneration and/or necrosis amongst other ﬁndings
were predominantely present in M. soleus and M. quadriceps.
Histopathological examination of the heart revealed no
abnormal ﬁndings.
Experiment 2:
Different skeletal muscles were collected for histopathology
scoring bilaterally to determine the distribution of the muscle
toxicity and to ensure optimal correlation of biomarker elevations
to histopathological ﬁndings.
In animals at 500 mg/kg cloﬁbrate QD minimal to mild skeletal
muscle ﬁber degeneration and/or regeneration and/or vacuolation
and or variation of myoﬁber diameter occurred in more than one
muscle. Cloﬁbrate for 7-Days.
Intersection Size Target Size Target% Intersection
11 74 14.9
11 82 13.4
11 88 12.5
9 70 12.9
9 86 10.5
8 81 9.9
5 38 13.2
6 62 9.7
6 66 9.1
5 46 10.9
6 68 8.8
10 177 5.6
5 49 10.2
7 118 5.9
7 119 5.9
5 67 7.5
5 67 7.5
3 27 11.1
7 138 5.1
5 80 6.3
7 143 4.9
5 81 6.2
5 81 6.2
Fig. 5. Cloﬁbrate-treated gene expression changes of mitochondria in M. soleus at 500 mg/kg QD.
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issimus dorsi and diaphragm were affected to a different extent. In
the muscles gastrocnemius, quadriceps, triceps, and longissimus
dorsi mainly deeper portions of the muscles were affected, which
included the gastrocnemius intermedius, the vastus intermedius,
and the deep portions of triceps and longissimus dorsi. In almost
all muscles, the histopathological ﬁndings occurred bilaterally,
except a few which occurred only unilateral. The ﬁndings of
myoﬁber degeneration and/or necrosis amongst other ﬁndings
were predominantely present in M. soleus and M. quadriceps (M.
vastus intermedius) (Table 4).
Histopathological examination of the heart revealed no
abnormal ﬁndings.
Fiber typing with anti-myosin slow and fast skeletal muscle
antibody of serial sections of muscles gastrocnemius/soleus,
quadriceps, triceps, and longissimus dorsi showed the distribution
of type I and type II muscle ﬁbers according to their anatomic
composition. The staining results showed that gastrocnemius
intermedius (Fig. 2), the vastus intermedius, and the deep portions
of triceps and longissimus dorsi had crowds of type I muscle ﬁbers
among the type II muscle ﬁbers.
Myosin slow positive and myosine fast negative muscle ﬁbers
showed degeneration and/or regeneration and vacuolation (Fig. 3)
which showed that cloﬁbrate induced skeletal muscle toxicity
affected mainly of type I muscle ﬁbers.
Immunohistochemistry with Fabp3 showed a loss of
Fabp3 staining of degenerated skeletal muscle ﬁbers especially
in animals 3001 and 3003 at 500 mg/kg cloﬁbrate QD (Fig. 4).
3.5. Gene expression
Experiment 1:
More than 3700 gene expression changes were observed in M.
soleus at 500 mg/kg cloﬁbrate QD (Filtered  +/ 2.0-fold change
and p < 0.01 in at least one animal).
The major down-regulated genes in M. soleus at 500 mg/kg
cloﬁbrate QD were related to the mitochondrial matrix and energy
metabolism. The major up-regulated genes in M. soleus at 500 mg/
kg cloﬁbrate QD were related to cellular structure, regeneration
and inﬂammation (repair). Major biochemical pathways perturbed
in M. soleus at 500 mg/kg cloﬁbrate QD were involved in energy
homeostasis including glucose utilization, fatty acid biosynthesis
(Table 6), e.g. an extensive decrease in expression of genes
associated with lipid metabolism. Cloﬁbrate treatment dysregu-
lated expression of many genes localized to mitochondria shown in
Fig. 5. Several genes were associated with fatty acid beta-oxidation
and regulation could be partially linked to PPARa agonism.
4. Discussion and conclusion
The aim of this investigation was to identify the most sensitive
biomarker for skeletal muscle toxicity of relatively low magnitude
and distribution in the musculature of the rat and to investigatesome of the other criteria the FDA expert working group deﬁned
like speciﬁcity and predectivity among others (Wallace et al.,
2004).
The ﬁrst experiment was designed to evaluate different skeletal
muscles (unilaterally) from different locations of the body which
are known to have type I and type II skeletal muscle ﬁbers in
different proportions. Experiment 2 was designed to evaluate the
distribution of skeletal muscle changes in more detail, e. g. limb
muscles were evaluated bilaterally according to their anatomic
composition to have improved correlation possibilities between
muscles, muscle ﬁber types affected and biomarker elevations.
Since blood collections in rodents are usually limited with regard
to volume, we included a urine collection as a less invasive
sampling method in experiment 2 to investigate myo additionally
in urine.
In both experiments, male SD rats were not uniformly
susceptible to cloﬁbrate induced skeletal muscle alterations.
Histopathologic skeletal muscle alterations including skeletal
myoﬁber degeneration/necrosis, regeneration, vacuolation and/
or variation in myoﬁber diameter were noted after 7-Day
treatment of cloﬁbrate at 150 mg/kg cloﬁbrate BID and 500 mg/
kg cloﬁbrate QD.
Since biomarker elevations in serum were considered as a
consequence leakage into the serum during skeletal myoﬁber
damage, the biomarker elevations were assessed for the correla-
tion to myoﬁber degeneration/necrosis and regeneration. In the
ﬁrst experiment, AST, Fabp3, Myl3, Prv, CK immunoreactivity, and
sTnI were increased statistically signiﬁcant in experiment 1 and
thus useful biomarkers to detect mild pathologic skeletal
myoﬁber alterations (Table 1). Fabp3, Myl3 and sTnI were useful
biomarkers to detect minimal pathologic skeletal myoﬁber
alterations but varied between animals. Fabp3 was elevated in
some animals, whereas Myl3 was elevated in all animals with
minimal pathologic skeletal myoﬁber alterations. sTnI was
elevated in all animals with minimal acute pathologic alterations
in skeletal myoﬁbers (degeneration/necrosis) but not with
regeneration (Tables 1 and 2). In the second experiment, AST,
Fabp3, Myl3, sTnI, and Myo in serum and Myo in urine were
elevated in animals with minimal to mild pathologic alterations
in skeletal myoﬁbers (statistically signiﬁcant for AST, Fabp3, and
Myl3 in serum and Myo in urine, Tables 3 and 5). Fabp3, Myl3,
sTnI in serum and were useful to detect minimal pathologic
alterations in skeletal myoﬁbers. The magnitude of biomarker
elevations in serum correlated with the magnitude of histopath-
ological alterations (Table 4). Taken together, in the two experi-
ments performed, Fabp3, Myl3, and sTnI were the biomarkers
which full ﬁlled the criteria of a useful biomarker which should be
speciﬁc, sensitive, predictive, robust, bridging preclinical and
clinical trials and non- or minimal-invasive and accessible
deﬁned by the FDA expert working group (Wallace et al.,
2004). However, Fabp 3 and Myl3 might only be speciﬁc in the
absence of cardiac toxicity.
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quadriceps muscle, which is due to the fact that the soleus consists
predominatly of type I myoﬁbers and the quadriceps has deep
portions which have a greater amount of type I myoﬁbers (M.
vastus intermedius). This could be shown by IHC of myosin slow
and fast (Figs. 2 and 3). Fabp3 IHC showed a loss of Fabp3 staining
of degenerated skeletal myoﬁbers especially in animals at 500 mg/
kg cloﬁbrate QD which correlated with elevations of Fabp3 in
serum (see Fig. 4 and Table 3).
Gene expression changes in the soleus muscle after cloﬁbrate
treatment at 500 mg/kg cloﬁbrate QD showed that mitochondria
may be the target substructure of the myoﬁbers. Cloﬁbrate
treatment dysregulated expression of many genes localized to
mitochondria. Several genes were associated with fatty acid beta-
oxidation and regulation could be partially linked to PPARa
agonism, therefore cloﬁbrate induced skeletal muscle alterations
in the M. soleus might be partially due to mitochondrial
dysfunction. Brunmair et al. (2004) also linked cloﬁbrate related
skeletal muscle toxicity to impairment of mitochondrial function
(in vitro). In particular, they showed that ﬁbrates inhibit the
mitochondrial respiratory complex I to different extends. Since
fatty acid binding protein 3 (Fabp 3) modulates the fatty acid
uptake in muscle cells (skeletal muscle and heart) the gene
expression changes can be directly correlated to the Fabp 3 loss in
damaged muscle and the release into serum.
In conclusion, Fabp3, Myl3 and sTnI were the most useful
biomarkers to detect cloﬁbrate-induced minimal pathologic
skeletal myoﬁber alterations although values varied between
animals. M. soleus and M. quadriceps were the most useful
muscles for detection of cloﬁbrate-induced lesions.
Experiments presented in this investigation are part of a large
project to characterize skeletal muscle biomarkers and include
parts of this project only.
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